Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company that develops therapies based on its proprietary TransCon technology platform to address unmet medical needs globally. The company's primary marketed product is SKYTROFA, a once-weekly injection for treating pediatric patients with growth hormone deficiency. It also offers YORVIPATH, a once-daily subcutaneous injection for adults with chronic hypoparathyroidism. Additionally, Ascendis has a pipeline of clinical-stage product candidates focusing on endocrinology rare diseases and oncology. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ASND. Its shares trade in US Dollars (USD). The company is headquartered in Denmark but is listed on a US exchange, making it accessible to international investors. The use of USD as the trading currency facilitates investment from US-based and global investors who prefer dollar-denominated securities.

Ascendis Pharma operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on developing innovative therapies for endocrine disorders and oncology. Its TransCon technology platform enables the design of prodrugs with sustained release profiles, aiming to improve patient outcomes and convenience. The company's work in biotechnology involves research, clinical development, and commercialization of treatments for rare diseases and other serious conditions.

Ascendis Pharma is headquartered in Hellerup, Denmark, and serves global markets. The company's products, such as SKYTROFA and YORVIPATH, are marketed internationally, with a focus on the United States and other regions. Its pipeline includes therapies for endocrinology rare diseases and oncology, targeting patients worldwide. The company's global reach is supported by its listing on the NasdaqGS, which provides access to US capital markets and investors.

Ascendis Pharma's main approved products are SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency and YORVIPATH (palopegteriparatide) for chronic hypoparathyroidism in adults. Both are based on the TransCon technology, which allows for less frequent dosing. The company's pipeline includes several clinical-stage candidates for endocrinology rare diseases, such as TransCon CNP for achondroplasia and TransCon PTH for hypoparathyroidism. Additionally, Ascendis is advancing oncology therapeutic candidates, including TransCon IL-2 β/γ and TransCon TLR7/8 agonist, aiming to address various cancers.